MXC takes first steps into pharmaceutical world
MGC Pharma (ASX:MXC) has taken the first steps into the world pharmaceuticals, developing an R&D agreement with an Israeli company to develop technology which can deliver pharmaceuticals directly to the brain.
It told its shareholders today that it had entered a collaboration agreement with SipNose, which has been hard at work developing the SipNose device.
The device, pictured below, promises to bypass the ‘blood brain barrier’ to deliver pharmaceuticals directly to the brain – leading to more effective treatment.
Normally drugs need to be absorbed into the bloodstream of a patient before making their way to the effective areas.
It opens up a new treatment option for diseases such as Alzheimer’s, Parkinson’s, and epilepsy.
MXC and SipNose are focusing on epilepsy, using a pharmaceutical product derived from medical cannabis in the form of cannabinoid compounds to help in the treatment of the disease.
According to Cure Epilepsy, 65 million people worldwide suffer some form of the disease.
The pair will enter into R&D, basing the research out of the Hadassah Medical Centre in Israel.
Should the R&D come off, MXC will investigate taking an exclusive global license for the SipNose device to be used to relieve epilepsy with a medical cannabis-based treatment.
Managing director of MGC Pharma Nativ Segev said that the deal with SipNose was a signal that it was about to become a fully-fledged pharmaceutical player.
“This partnership represents our first step towards establishing MXC’s medical R&D operations,” he said. “Our partnership with SipNose also signals our commitment to becoming a leading medical cannabis pharmaceuticals company and accelerates our path to market.”
From cosmetics to pharma
MXC, a recent listing on the ASX following the recent completion of a reverse takeover of Erin Resources has thus far focused on the cosmetic rather than the pharmaceutical game.
It launched an initial range of 15 CBD based cosmetic products this year under its MGC DERMA brand – although it has flagged intentions to deliver a total of 50 CBD based cosmetic products in the first half of this year.
These include facial creams, eye serums, soaps, toners, and cleansing milks with compounds derived from medical cannabis.
It is thought, however, that the main game for MXC has been to get into the pharmaceutical market – and it has in the past sold ‘active pharmaceutical ingredients’ derived from cannabis to other pharmaceutical companies.
The move into R&D though effectively signals its market entry into the fully-fledged pharmaceutical market.
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.